Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Diffuse Midline Glioma, H3 K27M-Mutant: early-phase trial registry
12 of 12 indexed Diffuse Midline Glioma, H3 K27M-Mutant trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,429 of 28,707 conditions by registered trial count.
12 US clinical trials · 12 currently recruiting · #1,429 of 28,707 conditions by registered trial count
Diffuse Midline Glioma, H3 K27M-Mutant: 12 US clinical trials tracked, 12 recruiting.
Diffuse Midline Glioma, H3 K27M-Mutant is the subject of 12 registered US clinical trials on ClinicalTrials.gov, 12 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most active sponsor is Nationwide Children's Hospital, running 2 of these trials.
Enrollment posture brief
Registry condition diffuse-midline-glioma-h3-k27m-mutant
OPEN 12 | RECR 100% | LATE 0 | EARLY 10 | RANK #1429 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
Diffuse Midline Glioma, H3 K27M-Mutant lists 12 open slots (100% of 12 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Diffuse Midline Glioma, H3 K27M-Mutant on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Diffuse Midline Glioma, H3 K27M-Mutant is recruiting above its size-band peers.
12 of 12 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Diffuse Midline Glioma, H3 K27M-Mutant research.
Nationwide Children's Hospital accounts for 2 of 12 trials (16.7%). 10 distinct sponsors appear on at least one study for this condition label.
-
Most Diffuse Midline Glioma, H3 K27M-Mutant trials plan to enrol fewer than 100 people.
Median target enrolment is 48 among the 12 trials that report a genuine target (sentinel values excluded). 8 of those (66.7%) plan for fewer than 100 participants.
-
Diffuse Midline Glioma, H3 K27M-Mutant research is mostly interventional.
10 interventional and 2 observational studies make up this index (83.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
12 total, page 1 of 1
International Diffuse Intrinsic Pontine Glioma (DIPG)/Diffuse Midline Glioma (DMG) Registry and Repository
Children's Hospital Medical Center, Cincinnati
NCT03101813
Combination Therapy for the Treatment of Diffuse Midline Gliomas
University of California, San Francisco
NCT05009992
Targeted Pediatric High-Grade Glioma Therapy
Nationwide Children's Hospital
NCT05839379
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Nationwide Children's Hospital
NCT05843253
Study of Olutasidenib and Temozolomide in HGG
Rigel Pharmaceuticals
NCT06161974
Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors
St. Jude Children's Research Hospital
NCT05835687
rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG
Ann & Robert H Lurie Children's Hospital of Chicago
NCT04943848
Stereotactic Biopsy Split-Course Radiation Therapy in Diffuse Midline Glioma, SPORT-DMG Study
Mayo Clinic
NCT05077735
CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young Adults
OX2 Therapeutics
NCT06305910
Atovaquone Combined With Radiation in Children With Malignant Brain Tumors
Emory University
NCT06624371
Genetically Modified Cells (KIND T Cells) for the Treatment of HLA-A*0201-Positive Patients With H3.3K27M-Mutated Glioma
University of California, San Francisco
NCT05478837
FUS Etoposide for DMG
Columbia University
NCT05762419
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Diffuse Midline Glioma, H3 K27M-Mutant records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Diffuse Midline Glioma, H3 K27M-Mutant trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Diffuse Midline Glioma, H3 K27M-Mutant page
12 registered trials, 12 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 12 Diffuse Midline Glioma, H3 K27M-Mutant trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Nationwide Children's Hospital sponsors the most Diffuse Midline Glioma, H3 K27M-Mutant trials on record, review their full trial history before evaluating a specific study. See Nationwide Children's Hospital's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Diffuse Midline Glioma, H3 K27M-Mutant condition card totals 12 registered trials; most-linked intervention Radiation Therapy; top US site state Ohio. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.